Quantcast

Latest Treatment of ulcerative colitis Stories

2012-08-16 13:08:51

Oral drug shows clinical response and remission in some patients An investigational drug currently under FDA review for the treatment of rheumatoid arthritis has now shown positive results in patients with moderate-to-severe ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine. The study will appear in the August 16, 2012 issue of the New England Journal of Medicine (NEJM). Results from the phase 2 clinical trial showed the drug...

2012-06-07 08:43:41

Study published in Science indicates that fungus plays a role in inflammatory bowel disease Cedars-Sinai researchers say their examination of the fungi in the intestines suggests an important link between these microbes and inflammatory diseases such as ulcerative colitis. In the new study, published in the June 8 issue of Science, researchers at Cedars-Sinai's Inflammatory Bowel and Immunobiology Research Institute identified and characterized the large community of fungi inhabiting...

2012-03-12 21:17:38

Many children with Crohn´s disease and ulcerative colitis who received treatment through ImproveCareNow, a national quality improvement and research network, ceased to have symptoms and no longer needed to take steroids for disease management. These are the findings from a study appearing in Pediatrics that examined the ImproveCareNow network´s quality improvement efforts and their impact on outcomes. In this study, the proportion of children with Crohn´s disease who were in...

2011-07-18 06:00:00

PHILADELPHIA, July 18, 2011 /PRNewswire/ -- Shire plc (LSE: SHP; NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved Lialda® (mesalamine) Delayed Release Tablets for the maintenance of remission in patients with ulcerative colitis. This approval is based on results from a six-month study demonstrating the safety and effectiveness of Lialda in maintaining endoscopic remission in adult...

2011-06-22 02:00:00

HEIDELBERG, Germany, June 22, 2011 /PRNewswire/ -- - Primary Endpoint Met Lipid Therapeutics, a biotechnology company focused on novel treatments for inflammatory bowel disease, today announced positive topline results from a Phase IIb clinical trial with its lead product, LT-02, in patients with ulcerative colitis. LT-02 is a controlled release formulation of phosphatidylcholine that has been specifically designed to treat ulcerative colitis by improving the barrier...

2011-06-14 05:18:00

UPPER SADDLE RIVER, N.J., June 14, 2011 /PRNewswire/ -- WellApps, Inc. announced today the newest release of GI Monitor, its symptom tracking app for (IBD) Crohn's and Ulcerative Colitis. Co-Founder Edward Shin, MD, says, "We're particularly excited about the new release since GI Monitor has recently quadrupled its user-base. This scale is providing some powerful real-time data and we know what an engaged mobile community can mean for patients." One of those patients is Brett Shamosh,...

2011-04-02 01:50:49

Ulcerative colitis (UC) is an inflammatory bowel disease thought to be related to aberrant activation of the immune system in the intestine. Recent research has also suggested that regulated cell death (apoptosis) of the intestinal epithelial cells is a contributing factor to the pathogenesis. However, the molecular mechanisms that control the cellular response to inflammation are incompletely understood. In this paper, Lin Zhang, at the University of Pittsburgh, in Pennsylvania, found that...

2011-01-06 07:00:00

OKLAHOMA CITY, Jan. 6, 2011 /PRNewswire/ -- Altheus Therapeutics, Inc., announced that it has completed a two dose, double-blind, active-controlled Phase I clinical trial of the safety and tolerability of Zoenasa(TM) Rectal Suspension in adult patients with left-sided, or distal, ulcerative colitis. No serious adverse events were experienced by patients in this study. "We are excited to have achieved this milestone, as it prepares Altheus to begin our planned Phase II clinical program to...

2010-08-02 07:00:00

WALTHAM, Mass., Aug. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 63 percent of surveyed U.S. gastroenterologists prescribe Abbott's Humira off-label for the treatment of ulcerative colitis. According to the new report entitled Treatment Algorithms in Ulcerative Colitis, surveyed gastroenterologists most often prescribe Humira for ulcerative colitis for patients with loss of response,...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.